Where every line comes from.
Every record and every pharmacology property cites a public source. State rules link to the official text and show when they were last checked. Data as of 2026-11-09.
01 State rules
Official text governs · All state materialsColorado Natural Medicine Program (Office of Natural Medicine Licensure, Division of Professions and Occupations).
4 CCR 755-1.
Applies to every participant regardless of medication: 2.2(A)(4), 6.15(C)(2)(c)(2), 6.16(F)(1), 6.17(C), 2.2(A)(9).
Oregon Psilocybin Services (Oregon Health Authority).
OAR 333-333-5050 and the Client Information Form.
Applies to every participant regardless of medication: 333-333-5050(3)(b), 333-333-5050(3)(d).
New Mexico Medical Psilocybin Program (Department of Health).
Proposed 7.35.3 NMAC.
02 Product labels
US prescribing information or OTC Drug Facts, via DailyMed. Each record links its own label; flags and half-lives are checked against the label text.
For medications not sold in the US: the EU Summary of Product Characteristics or equivalent, linked per record.
03 Reference works
Cited by page| Bazire S. Psychotropic Drug Directory 2018. Lloyd-Reinhold Publications, 2018. ISBN 978-0-9569156-4-1 |
| Brunton LL, Knollmann BC (eds). Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th ed. McGraw Hill, 2023. ISBN 978-1-264-25807-9 |
| Preston CL (ed). Stockley’s Drug Interactions, 11th ed. Pharmaceutical Press, 2016. ISBN 978-0-85711-270-5 |
| Taylor DM, Barnes TRE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry, 15th ed. Wiley, 2025. ISBN 978-1-394-23876-7 |
| AHFS Drug Information (American Society of Health-System Pharmacists), professional monograph via Drugs.com (per-drug link) |
| Other public reference page (per-entry link) |
| StatPearls (NCBI Bookshelf), drug monograph Indications section (per-drug link) |
| Vicente LLP. DEA places three kratom-related substances in Schedule I as 7-OH scheduling remains pending. September 9, 2026. |
04 Government and databases
05 Papers
145 · by first author| Abukahok N, Fitzgerald ND, Palamar JJ. An update on the epidemiology of tusi ("pink cocaine"). Curr Addict Rep 2025;12. doi:10.1007/s40429-025-00706-y |
| AJMC. FDA panel backs 6 peptides for compounding (PCAC, July 2026). link |
| Avula B, Wang YH, Rumalla CS, Smillie TJ, Khan IA. Simultaneous determination of alkaloids and flavonoids from aerial parts of Passiflora species and dietary supplements using UPLC-UV-MS and HPTLC. Nat Prod Commun 2012;7(9):1177-80. link |
| Bäckberg M, Beck O, Helander A. Phencyclidine analog use in Sweden—intoxication cases involving 3-MeO-PCP and 4-MeO-PCP from the STRIDA project. Clin Toxicol (Phila) 2015;53(9):856–864. doi:10.3109/15563650.2015.1079325 |
| Baggott MJ, Garrison KJ, Coyle JR, et al. Effects of the psychedelic amphetamine MDA (3,4-methylenedioxyamphetamine) in healthy volunteers. J Psychoactive Drugs 2019;51(2):108–117. doi:10.1080/02791072.2019.1593560 |
| Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004;4(5):281–297. doi:10.2165/00129784-200404050-00002 |
| Balíková M. Nonfatal and fatal DOB (2,5-dimethoxy-4-bromoamphetamine) overdose. Forensic Sci Int 2005;153(1):85–91. doi:10.1016/j.forsciint.2005.04.022 |
| Barnett BS, Koons CJ, Van den Eynde V, et al. Hypertensive emergency secondary to combining psilocybin mushrooms, extended release dextroamphetamine-amphetamine, and tranylcypromine. J Psychoactive Drugs 2024;57(3):297–303. doi:10.1080/02791072.2024.2368617 |
| Bazydlo LAL, Larkey NE. Testing strategies and the emergence of designer benzodiazepines. Clin Lab Med 2025;45(2):305–314. doi:10.1016/j.cll.2025.01.013 |
| Becker AM, Holze F, Grandinetti T, et al. Acute effects of psilocybin after escitalopram or placebo pretreatment. Clin Pharmacol Ther 2022;111(4):886–895. doi:10.1002/cpt.2487 |
| Becker AM, Humbert-Droz M, Mueller L, et al. Acute effects and pharmacokinetics of LSD after paroxetine or placebo pre-administration in a randomized, double-blind, cross-over phase I trial. Clin Pharmacol Ther 2025;117(6):1784–1792. doi:10.1002/cpt.3618 |
| Berar A, Allain JS, Allard S, et al. Intoxication with 3-MeO-PCP alone: a case report and literature review. Medicine (Baltimore) 2019;98(52):e18295. doi:10.1097/MD.0000000000018295 |
| Berquist MD, Gannon BM, Honeywell KM, et al. Interoceptive effects of N-substituted lysergamides in rats: role of agonist affinity at 5-hydroxytryptamine receptors and in vivo metabolism to lysergic acid diethylamide. J Pharmacol Exp Ther 2026:104988. doi:10.1016/j.jpet.2026.104988 |
| Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 1996;14:425–436. doi:10.1016/0893-133X(95)00145-4 |
| Bonson KR, Murphy DL. Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 1996;73:229–233. doi:10.1016/0166-4328(96)00102-7 |
| Bowen JS, Davis GB, Kearney TE, Bardin J. Diffuse vascular spasm associated with 4-bromo-2,5-dimethoxyamphetamine ingestion. JAMA 1983;249(11):1477–1479. PMID 6827726. link |
| Brandt SD, Kavanagh PV, Westphal F, et al. Return of the lysergamides. Part III: analytical characterization of N-ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD). Drug Test Anal 2017;9(10):1641–1649. doi:10.1002/dta.2196 |
| Brandt SD, Walters HM, Partilla JS, et al. The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats. Psychopharmacology (Berl) 2020;237(12):3703–3714. doi:10.1007/s00213-020-05648-z |
| Chen J, Wang Z, Yong CY, et al. Elucidating the Phase I metabolism of psilocin in vitro. Arch Toxicol 2025;99(3):1085–1094. doi:10.1007/s00204-024-03952-7 |
| Chisamore N, Kaczmarek ES, Doyle Z, et al. Comparing antidepressant effects of psilocybin-assisted psychotherapy in individuals unmedicated at screening versus individuals discontinuing medications. Can J Psychiatry 2025;70(10):759–767. doi:10.1177/07067437251328316 |
| Chu NS. Effects of betel chewing on the central and autonomic nervous systems. J Biomed Sci 2001;8(3):229–236. doi:10.1007/BF02256596 |
| Cilia R, Laguna J, Cassani E, et al. Daily intake of Mucuna pruriens in advanced Parkinson's disease: a 16-week, noninferiority, randomized, crossover, pilot study. Parkinsonism Relat Disord 2018;49:60-66. doi:10.1016/j.parkreldis.2018.01.014 |
| Cilia R, Laguna J, Cassani E, et al. Mucuna pruriens in Parkinson disease: a double-blind, randomized, controlled, crossover study. Neurology 2017;89(5):432-438. doi:10.1212/WNL.0000000000004175 |
| Cohen PA, Travis JC, Keizers PHJ, Deuster P, Venhuis BJ. Four experimental stimulants found in sports and weight loss supplements: 2-amino-6-methylheptane (octodrine), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylamylamine (1,3-DMAA) and 1,3-dimethylbutylamine (1,3-DMBA). Clin Toxicol (Phila) 2018;56(6):421-426. doi:10.1080/15563650.2017.1398328 |
| Copeland CS, Hudson S, Treble R, Hamnett HJ. The first fatal intoxication with 3-MeO-PCP in the UK and a review of the literature. J Anal Toxicol 2022;46(5):461–470. doi:10.1093/jat/bkac015 |
| Correia MS, Gonzaga MJ, Temple C, Gerona RR. Quantitative analysis of recreational psychoactive mushroom gummies in Portland, Oregon. Clin Toxicol (Phila) 2025;63(4):261-266. doi:10.1080/15563650.2025.2450240 |
| Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metab 2022;34(9):1234–1247. doi:10.1016/j.cmet.2022.07.013 |
| Da Broi U, Colatutto A, Sala P, Desinan L. Medico legal investigations into sudden sniffing deaths linked with trichloroethylene. J Forensic Leg Med 2015;34:81–87. doi:10.1016/j.jflm.2015.05.016 |
| Dahan A, Franko TS, Carroll JW, et al. Fact vs. fiction: naloxone in the treatment of opioid-induced respiratory depression in the current era of synthetic opioids. Front Public Health 2024;12:1346109. doi:10.3389/fpubh.2024.1346109 |
| de Sousa Fernandes Perna EB, Theunissen EL, Dolder PC, et al. Safety profile and neurocognitive function following acute 4-fluoroamphetamine (4-FA) administration in humans. Front Pharmacol 2018;9:713. doi:10.3389/fphar.2018.00713 |
| Do A, Michaud V, Stephan JF, et al. Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report. Front Psychiatry 2024;15:1394962. doi:10.3389/fpsyt.2024.1394962 |
| Dosoky NS, Shah SA, Dawson JT, et al. Chemical composition, market survey, and safety assessment of blue lotus (Nymphaea caerulea Savigny) extracts. Molecules 2023;28(20):7014. doi:10.3390/molecules28207014 |
| Edwards C, Van Gerpen S, Anand V. New-onset seizures in an adolescent following use of LSD while on low-dose lithium therapy: a case study. S D Med 2024;77(1):31–35. link |
| Eghdami S, Eissazade N, Heidari Mokarar M, et al. The safety and efficacy of N-acetylcysteine as an augmentation in the treatment of obsessive-compulsive disorder in adults: a systematic review and meta-analysis of randomized clinical trials. Front Psychiatry 2024;15:1421150. doi:10.3389/fpsyt.2024.1421150 |
| El Balkhi S, Coutaz-Fluck C, Moreau F, Paraf F, Gaulier JM. Is it worth carrying out determination of N-butane in postmortem samples? A case report and a comprehensive review of the literature. Int J Legal Med 2016;130(5):1223–1229. doi:10.1007/s00414-015-1260-9 |
| Erritzoe D, Barba T, Spriggs MJ, et al. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. J Psychopharmacol 2024;38(5):458–470. doi:10.1177/02698811241237870 |
| Falchi-Carvalho M, Palhano-Fontes F, Wießner I, et al. Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression. Neuropsychopharmacology 2025;50(6):895–903. doi:10.1038/s41386-025-02091-6 |
| Fisher AA, Purcell P, Le Couteur DG. Toxicity of Passiflora incarnata L. J Toxicol Clin Toxicol 2000;38(1):63-6. doi:10.1081/clt-100100919 |
| Gerostamoulos D, Glowacki L, Pricone M, et al. Fatal intoxications from a combination of 4-fluoroamphetamine and 25C-NBOMe. J Anal Toxicol 2023;47(2):191–196. doi:10.1093/jat/bkac059 |
| Glatfelter GC, Pottie E, Partilla JS, et al. Structure–activity relationships for psilocybin, baeocystin, aeruginascin, and related analogues to produce pharmacological effects in mice. ACS Pharmacol Transl Sci 2022;5(11):1181–1196. doi:10.1021/acsptsci.2c00177 |
| Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res 1999;16(9):1412–1416. doi:10.1023/a:1018955126402 |
| Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology 2023;48(10):1492–1499. doi:10.1038/s41386-023-01648-7 |
| Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Brain Res Rev 1994;19(2):180-222. doi:10.1016/0165-0173(94)90011-6 |
| Gresnigt FMJ, Snik A, Franssen EJF, et al. 4-Fluoroamphetamine (4-FA) intoxication results in exaggerated blood pressure effects compared to MDMA and amphetamine: a retrospective analysis. J Am Coll Emerg Physicians Open 2022;3(5):e12813. doi:10.1002/emp2.12813 |
| Grimley Evans J, Malouf R, Huppert F, van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people. Cochrane Database Syst Rev 2006;(4):CD006221. doi:10.1002/14651858.CD006221 |
| Grumann C, Henkel K, Brandt SD, et al. Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration. Drug Test Anal 2020;12(8):1144–1153. doi:10.1002/dta.2821 |
| Gukasyan N, Griffiths RR, Yaden DB, et al. Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. J Psychopharmacol 2023;37:707–716. doi:10.1177/02698811231179910 |
| Guo J, Chen H, Zhang X, et al. The effect of berberine on metabolic profiles in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Oxid Med Cell Longev 2021;2021:2074610. doi:10.1155/2021/2074610 |
| Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol 2012;68(2):213-7. doi:10.1007/s00228-011-1108-2 |
| Hajek T, Munthe S, Licht RW. Lithium orotate: distinct compound or simply Li(+) after administration? Br J Psychiatry 2026. doi:10.1192/bjp.2026.10699 |
| Halberstadt AL, Chatha M, Klein AK, et al. Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD). Neuropharmacology 2020;172:107856. doi:10.1016/j.neuropharm.2019.107856 |
| Halberstadt AL. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine. Pharmacol Biochem Behav 2016;143:1–10. doi:10.1016/j.pbb.2016.01.005 |
| Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18. doi:10.1177/02698811231211219 |
| Hammoud F, Ismail A, Zaher R, El Majzoub R, Abou-Abbas L. Mucuna pruriens treatment for Parkinson disease: a systematic review of clinical trials. Parkinsons Dis 2025;2025:1319419. doi:10.1155/padi/1319419 |
| Han DD, Gu HH. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 2006;6:6. doi:10.1186/1471-2210-6-6 |
| Harvey AL, Young LC, Viljoen AM, Gericke NP. Pharmacological actions of the South African medicinal and functional food plant Sceletium tortuosum and its principal alkaloids. J Ethnopharmacol 2011;137(3):1124-9. doi:10.1016/j.jep.2011.07.035 |
| Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 2009;6:31. doi:10.1186/1743-7075-6-31 |
| Hill SL, Harbon SCD, Coulson J, et al. Methoxetamine toxicity reported to the National Poisons Information Service: clinical characteristics and patterns of enquiries. Emerg Med J 2014;31(1):45–47. doi:10.1136/emermed-2012-202251 |
| Huo S, London K, Murphy L, et al. Notes from the field: suspected medetomidine withdrawal syndrome among fentanyl-exposed patients — Philadelphia, Pennsylvania, September 2024–January 2025. MMWR 2025;74:266–268. doi:10.15585/mmwr.mm7415a2 |
| Isbell H, Wolbach AB, Wikler A, Miner EJ. Cross tolerance between LSD and psilocybin. Psychopharmacologia 1961;2:147–159. doi:10.1007/BF00407974 |
| Jamshidi N, Cohen MM. The clinical efficacy and safety of tulsi in humans: a systematic review of the literature. Evid Based Complement Alternat Med 2017;2017:9217567. doi:10.1155/2017/9217567 |
| Jansson R, Lindström B, Dahlberg PA. Pharmacokinetic properties and bioavailability of methimazole. Clin Pharmacokinet 1985;10(5):443–450. doi:10.2165/00003088-198510050-00006 |
| Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med 2023;389(6):514–526. doi:10.1056/NEJMoa2301972 |
| Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148(10):1301–1308. doi:10.1176/ajp.148.10.1301 |
| Jevtović-Todorović V, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med 1998;4(4):460–463. doi:10.1038/nm0498-460 |
| Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol 2008;22(6):603–620. doi:10.1177/0269881108093587 |
| Jones NT, Wagner L, Hahn MCP, Scarlett CO, Wenthur CJ. In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin. Front Psychiatry 2024;14:1303365. doi:10.3389/fpsyt.2023.1303365 |
| Jouney EA. Phenibut (beta-phenyl-gamma-aminobutyric acid): an easily obtainable 'dietary supplement' with propensities for physical dependence and addiction. Curr Psychiatry Rep 2019;21(4):23. doi:10.1007/s11920-019-1009-0 |
| Keeler MH. Chlorpromazine antagonism of psilocybin effect. Int J Neuropsychiatry 1967;3:66–71. |
| Knuijver T, Schellekens A, Belgers M, et al. Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study. Addiction 2022;117(1):118–128. doi:10.1111/add.15448 |
| Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules 2015;20(2):2208–2228. doi:10.3390/molecules20022208 |
| Kuc J, Kettner H, Rosas F, et al. Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey. Psychopharmacology (Berl) 2022;239(5):1425–1440. doi:10.1007/s00213-021-05999-1 |
| Kuypers KPC, De Sousa Fernandes Perna EB, Theunissen EL, et al. A first-in-man study with 4-fluoroamphetamine demonstrates it produces a mild psychedelic state. J Psychoactive Drugs 2019;51(3):225–235. doi:10.1080/02791072.2019.1569286 |
| Kwon O, Kim Y, Paek JH, et al. Chaga mushroom-induced oxalate nephropathy that clinically manifested as nephrotic syndrome: a case report. Medicine (Baltimore) 2022;101(10):e28997. doi:10.1097/MD.0000000000028997 |
| Lake S, Lucas P. Co-use of psychedelics with other substances: findings from the global psychedelic survey. J Psychopharmacol 2025;39(5):453–462. doi:10.1177/02698811241292956 |
| Lee MS, Lee HW, You S, Ha KT. The use of maca (Lepidium meyenii) to improve semen quality: a systematic review. Maturitas 2016;92:64-69. doi:10.1016/j.maturitas.2016.07.013 |
| Leisegang K, Finelli R, Sikka SC, Panner Selvam MK. Eurycoma longifolia (Jack) improves serum total testosterone in men: a systematic review and meta-analysis of clinical trials. Medicina (Kaunas) 2022;58(8):1047. doi:10.3390/medicina58081047 |
| Liu S, O'Donnell J, Gladden RM, McGlone L, Chowdhury F. Trends in nonfatal and fatal overdoses involving benzodiazepines — 38 states and the District of Columbia, 2019–2020. MMWR 2021;70(34):1136–1141. doi:10.15585/mmwr.mm7034a2 |
| Luethi D, Walter M, Zhou X, et al. Para-halogenation affects monoamine transporter inhibition properties and hepatocellular toxicity of amphetamines and methcathinones. Front Pharmacol 2019;10:438. doi:10.3389/fphar.2019.00438 |
| Manevski N, Kurkela M, Höglund C, et al. Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases. Drug Metab Dispos 2010;38(3):386–395. doi:10.1124/dmd.109.031138 |
| Martin R, Buffenstein I, Cho D, Kiyokawa M. Toxidrome of an easily obtainable nootropic: a case report of phenibut intoxication and withdrawal delirium. J Clin Psychopharmacol 2023;43(6):507-510. doi:10.1097/JCP.0000000000001759 |
| Marwood L, Croal M, Mistry S, et al. The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression. J Psychiatr Res 2024;180:198–203. doi:10.1016/j.jpsychires.2024.10.009 |
| Mathews IM, Eastwood J, Lamport DJ, et al. Clinical efficacy and tolerability of lemon balm (Melissa officinalis L.) in psychological well-being: a review. Nutrients 2024;16(20):3545. doi:10.3390/nu16203545 |
| McBride MC. Bufotenine: toward an understanding of possible psychoactive mechanisms. J Psychoactive Drugs 2000;32(3):321–331. doi:10.1080/02791072.2000.10400456 |
| Mezaache S, Pochard L, Peyrière H, et al. Emerging new psychoactive ketamine analogues: patterns of use and health risks identified by the French Addictovigilance Network. Int J Drug Policy 2026;153:105326. doi:10.1016/j.drugpo.2026.105326 |
| Morgan A, Stevens J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. J Altern Complement Med 2010;16(7):753-9. doi:10.1089/acm.2009.0342 |
| Moss MJ, Hendrickson RG. Toxicity of muscimol and ibotenic acid containing mushrooms reported to a regional poison control center from 2002-2016. Clin Toxicol (Phila) 2019;57(2):99-103. doi:10.1080/15563650.2018.1497169 doi:10.1080/15563650.2018.1497169 |
| Mukai T, Kishi T, Matsuda Y, Iwata N. A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol 2014;29(1):55-63. doi:10.1002/hup.2369 |
| Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med 2008;149(9):601–611. doi:10.7326/0003-4819-149-9-200811040-00003 |
| Nayak SM, Gukasyan N, Barrett FS, et al. Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures. Pharmacopsychiatry 2021. doi:10.1055/a-1524-2794 |
| Nicholas CR, Banks MI, Lennertz RC, et al. Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience. Transl Psychiatry 2024;14:372. doi:10.1038/s41398-024-03059-8 |
| Nicholas CR, Horton DM, Malicki J, et al. Psilocybin for opioid use disorder in two adults stabilized on buprenorphine: a technical report on study modifications and preliminary findings. Psychedelic Med 2023;1(4):253–261. doi:10.1089/psymed.2023.0012 |
| Ochi T, Sakamoto M, Minamida A, et al. Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423. Bioorg Med Chem Lett 2005;15:1055. doi:10.1016/j.bmcl.2004.12.028 |
| Olatunji TL, Siebert F, Adetunji AE, et al. Sceletium tortuosum: a review on its phytochemistry, pharmacokinetics, biological and clinical activities. J Ethnopharmacol 2021;280:114476. doi:10.1016/j.jep.2021.114476 |
| Ott J. Pharmañopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine. J Psychoactive Drugs 2001;33(3):273–281. doi:10.1080/02791072.2001.10400574 |
| Papaseit E, Farré M, Pérez-Mañá C, et al. Acute pharmacological effects of 2C-B in humans: an observational study. Front Pharmacol 2018;9:206. doi:10.3389/fphar.2018.00206 |
| Pauzé DK, Brooks DE. Lithium toxicity from an Internet dietary supplement. J Med Toxicol 2007;3(2):61–62. doi:10.1007/BF03160910 |
| Penzak SR, Bulloch M. Phenibut: review and pharmacologic approaches to treating withdrawal. J Clin Pharmacol 2024;64(6):652-671. doi:10.1002/jcph.2414 |
| Pepe M, Di Nicola M, Cocciolillo F, et al. 3-Methoxy-phencyclidine induced psychotic disorder: a literature review and an 18F-FDG PET/CT case report. Pharmaceuticals (Basel) 2024;17(4):452. doi:10.3390/ph17040452 |
| Piercey CJ, Hetelekides E, Karoly HC. Simultaneous cannabis and psychedelic use among festival and concert attendees in Colorado. J Cannabis Res 2024;6:29. doi:10.1186/s42238-024-00235-x |
| Poklis JL, Mulder HA, Halquist MS, et al. The blue lotus flower (Nymphea caerulea) resin used in a new type of electronic cigarette, the re-buildable dripping atomizer. J Psychoactive Drugs 2017;49(3):175-181. doi:10.1080/02791072.2017.1290304 |
| Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol 2016;26:756–766. doi:10.1016/j.euroneuro.2016.01.005 |
| Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2012;8(1):33–42. doi:10.1007/s13181-011-0193-z |
| Reckweg J, Mason NL, van Leeuwen C, et al. A phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-MeO-DMT formulation (GH001) in healthy volunteers. Front Pharmacol 2021;12:760671. doi:10.3389/fphar.2021.760671 |
| Resnick O, Krus DM, Raskin M. LSD-25 action in normal subjects treated with a monoamine oxidase inhibitor. Life Sci 1964;3:1207–1214. |
| Riess S, Chèze M, Muckensturm A, et al. 2-Fluorodeschloroketamine consumption: about two deaths and a case of self-mutilation. J Anal Toxicol 2024;48(5):398–404. doi:10.1093/jat/bkae021 |
| Roberts A, Korona-Bailey J, Mukhopadhyay S. Notes from the field: nitazene-related deaths — Tennessee, 2019–2021. MMWR 2022;71(37):1196–1197. doi:10.15585/mmwr.mm7137a5 |
| Rosenblat JD, et al. Antidepressant effects of psilocybin in the absence of psychedelic effects. Am J Psychiatry 2023 (letter). doi:10.1176/appi.ajp.20220835 |
| Roth BL, Gibbons S, Arunotayanun W, et al. The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS One 2013;8(3):e59334. doi:10.1371/journal.pone.0059334 |
| Sakai K, Bradley ER, Zamaria JA, et al. Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms. Psychopharmacology 2024;241(8):1617–1630. doi:10.1007/s00213-024-06585-x |
| Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976. doi:10.1007/s00213-022-06083-y |
| Schifano F, Catalani V, Sharif S, et al. Benefits and harms of 'smart drugs' (nootropics) in healthy individuals. Drugs 2022;82(6):633-647. doi:10.1007/s40265-022-01701-7 |
| Schifano F, Chiappini S, Miuli A, et al. New psychoactive substances (NPS) and serotonin syndrome onset: a systematic review. Exp Neurol 2021;339:113638. doi:10.1016/j.expneurol.2021.113638 |
| Schimpf M, Ulmer T, Hiller H, Barbuto AF. Toxicity from blue lotus (Nymphaea caerulea) after ingestion or inhalation: a case series. Mil Med 2023;188(7-8):usab328. doi:10.1093/milmed/usab328 |
| Shen HW, Jiang XL, Winter JC, Yu AM. Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab 2010;11(8):659–666. doi:10.2174/138920010794233495 |
| Siefried KJ, Freeman G, Roberts DM, et al. Inpatient GHB withdrawal management in an inner-city hospital in Sydney, Australia: a retrospective medical record review. Psychopharmacology (Berl) 2023;240(1):127–135. doi:10.1007/s00213-022-06283-6 |
| Siervo M, Lara J, Ogbonmwan I, Mathers JC. Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: a systematic review and meta-analysis. J Nutr 2013;143(6):818-26. doi:10.3945/jn.112.170233 |
| Singhani V, et al. Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: a narrative expert review. Nutr Clin Pract 2026;41(5):1318–1333. doi:10.1002/ncp.70180 |
| Sklerov J, Levine B, Moore KA, King T, Fowler D. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. J Anal Toxicol 2005;29(8):838–841. doi:10.1093/jat/29.8.838 |
| Soh J, Raventhiran S, Lee JH, et al. The effect of glycine administration on the characteristics of physiological systems in human adults: a systematic review. Geroscience 2024;46(1):219-239. doi:10.1007/s11357-023-00970-8 |
| Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 2004;32(6):587-94. doi:10.1124/dmd.32.6.587 |
| Strassman RJ. Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res 1996;73(1-2):121–124. doi:10.1016/0166-4328(96)00081-2 |
| Sutherland MH, Nicholas CR, Lennertz RC, et al. Electrophysiological effects of psilocybin co-administered with midazolam. Transl Psychiatry 2026;16. doi:10.1038/s41398-026-03894-x |
| Tang MHY, Li TC, Lai CK, et al. Emergence of new psychoactive substance 2-fluorodeschloroketamine: toxicology and urinary analysis in a cluster of patients exposed to ketamine and multiple analogues. Forensic Sci Int 2020;312:110327. doi:10.1016/j.forsciint.2020.110327 |
| Tap SC, Thomas K, Páleníček T, et al. Concomitant use of antidepressants and classic psychedelics: a scoping review. J Psychopharmacol 2025. doi:10.1177/02698811251368360 |
| Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab 2006;91(3):799–805. doi:10.1210/jc.2005-1536 |
| Thomann J, Kolaczynska KE, Stoeckmann OV, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol 2024;15:1391689. doi:10.3389/fphar.2024.1391689 |
| Thornton S, Lisbon D, Lin T, Gerona R. Beyond ketamine and phencyclidine: analytically confirmed use of multiple novel arylcyclohexylamines. J Psychoactive Drugs 2017;49(4):289–293. doi:10.1080/02791072.2017.1333660 |
| Thuy NHL, Tu VL, Thu LNA, et al. Pharmacological activities and safety of Ganoderma lucidum spores: a systematic review. Cureus 2023;15(9):e44574. doi:10.7759/cureus.44574 |
| Toennes SW, Schneider D, Pogoda W, et al. Pharmacokinetic properties of 4-fluoroamphetamine in serum and oral fluid after oral ingestion. Drug Test Anal 2019;11(7):1028–1034. doi:10.1002/dta.2595 |
| Ulbricht C, Conquer J, Flanagan K, et al. An evidence-based systematic review of tongkat ali (Eurycoma longifolia) by the Natural Standard Research Collaboration. J Diet Suppl 2013;10(1):54-83. doi:10.3109/19390211.2012.761467 |
| Uno T, Yasui-Furukori N. Effect of grapefruit juice in relation to human pharmacokinetic study. Curr Clin Pharmacol 2006;1(2):157–161. doi:10.2174/157488406776872550 |
| Vallianou NG, Kounatidis DC, Dalamaga M, et al. Alpha-lipoic acid as a trigger of insulin autoimmune syndrome: current evidence, a case-based approach, diagnostic pitfalls, and practical management. Metabol Open 2026;31:100491. doi:10.1016/j.metop.2026.100491 |
| van Amsterdam JGC, Nabben T, van den Brink W. Increasing recreational nitrous oxide use: should we worry? A narrative review. J Psychopharmacol 2022;36(8):943–950. doi:10.1177/02698811221082442 |
| Vandeputte MM, Krotulski AJ, Walther D, et al. Pharmacological evaluation and forensic case series of N-pyrrolidino etonitazene (etonitazepyne), a newly emerging 2-benzylbenzimidazole 'nitazene' synthetic opioid. Arch Toxicol 2022;96(6):1845–1863. doi:10.1007/s00204-022-03276-4 |
| Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997;54(1):49–55. doi:10.1001/archpsyc.1997.01830130055011 |
| Viti L, Tartaglione L, Rizzi A, et al. A case of Hirata syndrome in pregnancy induced by alpha-lipoic acid: diagnosis and management. AACE Endocrinol Diabetes 2025;12(2):84-88. doi:10.1016/j.aed.2025.03.012 |
| Vojtěchovský M, Hort V, Šafratová V. Influence of MAO inhibitors on psilocybine induced psychosis. Activitas Nervosa Superior 1968;10(3):278–279 (via Tap 2025). |
| Volak LP, Ghirmai S, Cashman JR, Court MH. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos 2008;36(8):1594–1605. doi:10.1124/dmd.108.020552 |
| Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 1998;9:3897–3902. doi:10.1097/00001756-199812010-00024 |
| Wolbach AB, Isbell H, Miner EJ. Cross tolerance between mescaline and LSD-25, with a comparison of the mescaline and LSD reactions. Psychopharmacologia 1962;3:1–14. doi:10.1007/BF00413101 |
| Wu F, Wang Y, Mei Q, et al. UGTs-mediated metabolic interactions contribute to enhanced anti-inflammation activity of Jinhongtang. J Ethnopharmacol 2023;304:116016. doi:10.1016/j.jep.2022.116016 |
| Xie W, Su F, Wang G, et al. Glucose-lowering effect of berberine on type 2 diabetes: a systematic review and meta-analysis. Front Pharmacol 2022;13:1015045. doi:10.3389/fphar.2022.1015045 |
| Zanda MT, Fadda P, Chiamulera C, Fratta W, Fattore L. Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects: a review of case reports and preclinical findings. Behav Pharmacol 2016;27(6):489–496. doi:10.1097/FBP.0000000000000241 |
| Zawilska JB, Kacela M, Adamowicz P. NBOMes — highly potent and toxic alternatives of LSD. Front Neurosci 2020;14:78. doi:10.3389/fnins.2020.00078 |